BridgeBio stock rises after $300 million royalty deal for European acoramidis sales

BridgeBio Pharma (BBIO) secured a $300 million upfront payment by monetizing 60% of its European acoramidis (Beyonttra) royalties to HealthCare Royalty and Blue Owl Capital, with total payments capped at 1.45 times the initial amount. This capital infusion is intended to strengthen its balance sheet, support the U.S. launch of Attruby, and advance its late-stage R&D pipeline. The transaction has garnered broad analyst optimism, with firms like Citi, Wolfe Research, H.C. Wainwright, Piper Sandler, and BMO Capital reiterating or initiating positive ratings and raising price targets, citing strong Attruby sales momentum and significant revenue growth projections, alongside the potential of pipeline assets like encaleret.

Analysis

BridgeBio Pharma has secured $300 million in non-dilutive, upfront financing by monetizing 60% of its European royalties for the drug acoramidis (branded Beyonttra). The agreement with HealthCare Royalty and Blue Owl Capital is strategically structured with a payment cap at 1.45 times the initial amount, allowing BridgeBio to retain significant long-term upside from future sales beyond this threshold. This capital infusion strengthens the company's balance sheet and provides dedicated funding for the critical U.S. launch of the same drug (branded Attruby) and for advancing late-stage R&D programs. The transaction has been met with broad analyst optimism, reinforcing the positive sentiment surrounding the company, which has already seen a 77% stock appreciation over the past year. Analysts from firms including Citi, Wolfe Research, and BMO Capital have issued positive ratings and increased price targets, citing strong near-term sales momentum for Attruby—with BMO projecting Q2 sales could beat consensus by 20-40%—and substantial long-term revenue growth potential, with Wolfe projecting $3.4 billion by 2028. Furthermore, a key future value driver is identified in the pipeline, particularly the Phase 3 CALIBRATE study for encaleret, with data expected in the second half of 2025.

Key Decisions for Investors

• The $300 million non-dilutive financing significantly de-risks the company's balance sheet, reducing the likelihood of a near-term equity raise to fund the Attruby launch and pipeline development.
• Investors should closely monitor upcoming quarterly sales figures for Attruby in the U.S., as strong performance could validate the bullish analyst consensus and serve as a key near-term catalyst for the stock.
• Beyond the commercial launch, a significant long-term catalyst is the Phase 3 topline data readout for encaleret, expected in the second half of 2025, which could unlock substantial value from the pipeline.
• Given the stock's 77% run-up in the past year and the wide analyst price target range of $41 to $95, investors should note the recent momentum, but the royalty deal's structure preserves significant long-term upside from acoramidis sales, supporting a positive long-term view.